General Information of Drug (ID: DM89QXT)

Drug Name
MET409
Indication
Disease Entry ICD 11 Status REF
Non-alcoholic steatohepatitis DB92.1 Phase 2 [1]
Drug Type
Small molecular drug
Cross-matching ID
TTD ID
DX56JK

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Farnesoid X-activated receptor (FXR) TTS4UGC NR1H4_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Non-alcoholic steatohepatitis
ICD Disease Classification DB92.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Farnesoid X-activated receptor (FXR) DTT NR1H4 5.72E-01 0.39 1.68
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04702490) Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Metacrine.